Inventor · disambiguated record
Martin L. Ogletree
Also filed as: OGLETREE MARTIN · OGLETREE MARTIN L
8 granted patents·9 pending applications·237 citations·filing 1987–2021
89Inventor score
Files withSQUIBB & SONS INC6CUMBERLAND PHARMACEUTICALS INC4BRISTOL MYERS SQUIBB CO2CUMBERLAND EMERGING TECH INC1CUMBERLAND EMERGING TECHNOLOGIES INC1
Top patents by PatentIndex Score
17 records- 0187US6509348B1Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combinationBRISTOL MYERS SQUIBB CO·Filed 1999·Granted Jan 21, 2003·76 cites·3 claims
- 0275US5312818AMethod of protecting against and/or treating ulcerative gastrointestinal conditions using a thromboxane A2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammationSQUIBB & SONS INC·Filed 1992·Granted May 17, 1994·40 cites·10 claims
- 0375US5262419AMethod for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activatorSQUIBB & SONS INC·Filed 1992·Granted Nov 16, 1993·34 cites·17 claims
- 0474US2020375953A1Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor AntagonistsCUMBERLAND PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 0573US4839384AMethod of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonistSQUIBB & SONS INC·Filed 1988·Granted Jun 13, 1989·19 cites·11 claims
- 0671US5066480AMethod of preventing or reducing adverse reactions to protamine using a thromboxane a2 receptor antagonistSQUIBB & SONS INC·Filed 1988·Granted Nov 19, 1991·16 cites·20 claims
- 0771US2020171007A1Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor AntagonistsCUMBERLAND PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 0869US2019343810A1Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor AntagonistsCUMBERLAND PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 0968US5605917AMethod of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogBRISTOL MYERS SQUIBB CO·Filed 1994·Granted Feb 25, 1997·37 cites·15 claims
- 1068US2019247365A1Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor AntagonistsCUMBERLAND PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1165US5162352A7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogsSQUIBB & SONS INC·Filed 1991·Granted Nov 10, 1992·8 cites·12 claims
- 1263US2017319554A1Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor AntagonistsCUMBERLAND EMERGING TECH INC·Filed 2017·Application pending·0 cites
- 1358US2013197044A1Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonistsPAVLIV LEO·Filed 2011·Application pending·0 cites
- 1457US2015297571A1Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor AntagonistsCUMBERLAND EMERGING TECHNOLOGIES INC·Filed 2015·Application pending·0 cites
- 1556US4808627AMethod of preventing or treating toxemia in pregnancy using a thromboxane A2 receptor antagonistSQUIBB & SONS INC·Filed 1987·Granted Feb 28, 1989·7 cites·17 claims
- 1655US2003109543A1Novel combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combinationFiled 2002·Application pending·0 cites
- 1754US2023129262A1Methods and pharmaceutical compositions of thromboxane a2 receptor antagonist for the treatment of covid-19OGLETREE MARTIN·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Martin L. Ogletree files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →